Caliway Biopharmaceuticals C, TW0006919004

Caliway starts CBL-514 phase 3, a 69.60 percent test for Caliway Biopharmaceuticals C stock

Published on 10/16/2026 at 11:32 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Caliway's CBL-514 cut visceral fat 12.01 percent in phase 2. Caliway Biopharmaceuticals C stock now heads toward phase 3 and November 11 results.

Clinical program advances toward phase 3

CBL-514 reduced subcutaneous fat by 69.60 percent in an October 2, 2026 phase 2 report.
Visceral fat fell 12.01 percent against a 5.68 percent placebo increase four weeks after treatment.
Caliway Biopharmaceuticals C expects its next results on November 11, 2026.

Caliway Biopharmaceuticals C, TW0006919004, Illustration mit AI erstellt.

Caliway Biopharmaceuticals C (ISIN TW0006919004) is moving CBL-514 into phase 3 after phase 2 data showed a 69.60 percent response in subcutaneous fat reduction. On October 2, 2026, Caliway Biopharmaceuticals said recruitment had started for the first of two randomized phase 3 trials.

Phase 2 results set the benchmark

The phase 2 result concerned abdominal subcutaneous fat. At the eight-week follow-up, 69.60 percent of treated participants had reduced fat volume by at least 150 mL, compared with 0 percent in the placebo group, according to the company release dated October 2, 2026.

The visceral-fat data added a second numerical signal. Four weeks after the final treatment, average visceral fat volume fell 12.01 percent from baseline in the CBL-514 group, while it increased 5.68 percent with placebo. The source reported a 17.69-percentage-point difference between the groups.

What does phase 3 test next?

The next stage shifts the question from early response to safety and efficacy in larger, placebo-controlled studies. The first trial is designed for nonsurgical abdominal fat reduction, and first results are expected at the end of 2027, according to the October 2, 2026 company release.

The clinical program has several milestones behind it. On September 23, 2026, Clival reported that the CBL-0202DD phase 2 study met its primary endpoint, with a 3.10-point average pain reduction at week 20 versus 1.90 points for placebo. On October 15, 2026, pharmaphorum highlighted the phase 3 transition and the 69.60 percent subcutaneous-fat response.

Results date sets the next checkpoint

The next scheduled reporting date is November 11, 2026. Investing.com lists that date for the next results announcement.

Clinical evidence drives the story

Caliway's investment case remains tied to whether early fat-reduction findings translate into repeatable phase 3 outcomes. The 12.01 percent visceral-fat reduction and the 69.60 percent subcutaneous-fat response provide measurable benchmarks, while the placebo comparisons give the later trials a clear standard.